Business
Placing
Placing.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 4679W Sareum Holdings PLC 14 November 2017 \n\n\n\n\n\n(AIM: SAR)\n\n\n14 November 2017\n\n\n\n\nSareum Holdings plc\n(\"Sareum\" or \"the Company\")\nPlacing\nSareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, announces that it has raised £700,000, before expenses, through a placement via Hybridan LLP as agent of the Company, of 100,000,000 new ordinary shares of 0.025p each in the capital of the Company (the \"Placing Shares\") at 0.7p per share.\nThe net proceeds of the placing will be used to progress the Company's drug development programmes as well as for working capital purposes. \nApplication has been made for the Placing Shares, which will rank pari passu with the Company's existing Ordinary Shares, to be admitted to trading on London Stock Exchange AIM (\"Admission\"). It is anticipated that Admission will become effective at 8.00 am on 22 November 2017.\nFollowing the admission of the Placing Shares to trading on AIM, the Company will have a total of 2,745,223,988 shares in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.\nFor further information, please contact: \n\n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser and Co-Broker)\n\n\n\n\nChris Fielding / James Sinclair-Ford\n\n\n020 7220 1666\n\n\n\n\nHybridan LLP (Co-Broker)\n\n\n \n\n\n\n\nClaire Noyce\n\n\n020 3764 2341\n\n\n\n\nCitigate Dewe Rogerson (Media enquiries)\n\n\n \n\n\n\n\nShabnam Bashir/ Mark Swallow/ David Dible\nShabnam Bashir/ Mark Swallow/ David Dible\n\n\n\n020 7282 9571\n020 7282 9571\n\n\n\n\nNotes for editors: \nSareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.\nIts most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and in clinical t...